A good measuring stick for the likely acceptance and use of the two recently FDA-approved obesity drugs Qsymia (phentermine/topiramate) and Belviq (lorcaserin hydrochloride) came at Obesity 2012, the annual Obesity Society conference held in San Antonio recently. Although only Qsymia is on the market, so far the consensus among the delegates at the conference appeared to be generally positive.